ライフサイエンスコーパス: estrogen receptor alpha

1 receptor coactivator 2, which interacts with estrogen receptor alpha.

2 e genes; vitellogenin, androgen receptor and estrogen receptor alpha.

3 l lineage specification, including FOXA1 and estrogen receptor alpha.

4 ty in E2-exposed HEK293T cells co-expressing estrogen receptor alpha.

5 d the ligand-dependent activation domains of estrogen receptor alpha.

6 CD133(hi) CSCs that expressed low levels of estrogen receptor alpha.

7 reased autophagy and decreased expression of estrogen receptor-alpha.

8 tein-coupled estrogen receptor (GPER/GPR30), estrogen receptor alpha-36 (ERalpha36), epidermal growth

9 We apply the model to data from estrogen receptor alpha activation in the MCF-7 breast c

10 pply our method to dissect the regulation of estrogen receptor-alpha activation in breast cancer to i

11 n response element (ERE) sequence to inhibit estrogen receptor-alpha activities.

12 egree show a greater effect on the levels of estrogen receptor-alpha activity and nuclear factor eryt

13 itro cellular toxicity, devoid of detectable estrogen receptor alpha affinity, displays high aqueous

14 gamma agonist) and 17beta-estradiol (E2; an estrogen receptor alpha agonist) nearly abolished TDCIPP

15 confirmed that in hypoxic mice inhibition of estrogen receptor alpha also has a therapeutic effect sp

16 ation between maternal LG and mRNA levels of estrogen receptor alpha and beta and the oxytocin recept

17 n regulating the transcriptional activity of estrogen receptor alpha and controlling the expression o

18 E2 substantially increases CaM binding to estrogen receptor alpha and GPER/GPR30.

19 cellular pathway in both tissues, including estrogen receptor alpha and peroxisome proliferator acti

20 In the MG there was overexpression of estrogen receptor alpha and progesterone receptor, loss

21 iption factor, which interacts directly with estrogen receptor alpha and regulates the expression of

22 stic disease and cancers retained functional estrogen receptor alpha and responded to retreatment wit

23 and glial profiles containing the classical estrogen receptors alpha and beta, and synaptic levels i

24 hat could be suppressed by inhibitors of the estrogen receptors alpha and beta, fibroblast growth fac

25 7beta-HSD5, 11beta-HSD1, 11beta-HSD2 and the estrogen receptors alpha and beta.

26 Furthermore, uterine ILC2s highly expressed estrogen receptor alpha, and in vitro culture of isolate

27 /progenitor activity, elevated expression of estrogen receptor alpha, and increased DNA damage in cel

28 ns, including HSP70 (heat-shock protein 70), estrogen receptor alpha, and RNA helicase A.

29 e expression and proliferation are driven by estrogen receptor alpha, and targeting this transcriptio

30 ough repression of E-cadherin, occludin, and estrogen receptor-alpha, and up-regulation of vimentin,

31 It acts as an ER (estrogen receptor) alpha antagonist in ER-positive breas

32 Estrogen and estrogen receptor alpha are required for the development

33 Estrogen and its nuclear receptor, estrogen receptor alpha, are necessary cofactors in the

34 cells within the AVPV/PeN highly co-express estrogen receptor alpha as well as glucocorticoid recept

35 r of genome-wide analyses have revealed that estrogen receptor alpha binding to and regulation of its

36 e chromatin architecture and allow FOXA1 and estrogen receptor alpha binding to transcriptional regul

37 ecreases the transcriptional activity of ER (estrogen receptor)-alpha but not ERbeta through the modu

38 Expression of estrogen receptor alpha changes across development in a

39 tration decreased AIRE thymic expression and estrogen receptor alpha-deficient mice did not show a se

40 of pharmacology and demonstrated the desired estrogen receptor alpha degrader-antagonist profile and

41 In mice lacking the liver estrogen receptor alpha, E2 after OVX limited adiposity

42 isplayed affinity for aromatase (Ki 442 nM), estrogen receptor-alpha (EC50 17 nM), and estrogen recep

43 (E)-norendoxifen were aromatase (Ki 48 nM), estrogen receptor-alpha (EC50 58.7 nM), and estrogen rec

44 Mutations in ESR1 that confer constitutive estrogen receptor alpha (ER) activity in the absence of

45 Phosphorylation of estrogen receptor alpha (ER) at serine 118 (pS118-ER) oc

46 We generated genetic deletions of four estrogen receptor alpha (ER) bound enhancers that regula

47 ast cancer patients with tumors that express estrogen receptor alpha (ER) generally respond well to h

48 been thought to be functionally connected to estrogen receptor alpha (ER) in breast cancer.

49 Estrogen receptor alpha (ER) is a key oncogene in endome

50 Estrogen signaling through estrogen receptor alpha (ER) plays a major role in endom

51 we found 3 lncRNA genes are associated with estrogen receptor alpha (ER) positive and ER negative su

52 The majority of human breast cancer is estrogen receptor alpha (ER) positive.

53 Knockdown of RAD21 altered estrogen receptor alpha (ER) recruitment at SOX4 and IL2

54 ox protein A1 (FOXA1) is a pioneer factor of estrogen receptor alpha (ER)-chromatin binding and funct

55 e success of approved systemic therapies for estrogen receptor alpha (ER)-positive breast cancer, dru

56 rovides a temporary relief for patients with estrogen receptor alpha (ER)-positive breast cancers.

57 ng, we used an integrative approach to study estrogen receptor alpha (ER).

58 vo tumor uptake compared with wild-type (WT)-estrogen receptor alpha (ER).

59 T2 promoter activity when cotransfected with estrogen receptor alpha (ER-alpha) after 17beta-estradio

60 heir abilities to inhibit aromatase, bind to estrogen receptor alpha (ER-alpha) and estrogen receptor

61 Estrogen receptor alpha (ER-alpha) forms a regulatory ne

62 Estrogen receptor alpha (ER-alpha) is a nuclear hormone

63 Approximately 80% of breast cancers are estrogen receptor alpha (ER-alpha) positive, and althoug

64 ed, dramatic estrogen-induced recruitment to estrogen receptor alpha (ER-alpha)-bound eRNA(+) active

65 Drugs that inhibit estrogen receptor-alpha (ER) activity have been highly s

66 Herein, we probed estrogen receptor-alpha (ER) and progesterone receptor (

67 ally required for response to two classes of estrogen receptor-alpha (ER) antagonists.

68 Tamoxifen is effective for treating estrogen receptor-alpha (ER) positive breast cancers.

69 e I IGF receptor (IGF1R) in combination with estrogen receptor-alpha (ER) targeting have been complet

70 -GAP (GTPase-activating protein), is also an estrogen receptor-alpha (ER) transcriptional co-represso

71 oligomerization states and mutants of GR and estrogen receptor-alpha (ER), which permitted us to reso

72 ied BRCA1 knockdown resulting in the loss of Estrogen Receptor-alpha (ER-alpha) expression and other

73 cord injury (SCI), or the involvement of the estrogen receptor-alpha (ER-alpha) in locomotor recovery

74 duce tamoxifen resistance through decreasing estrogen receptor-alpha (ER-alpha) level when cultured w

75 HE4 was found to interact with estrogen receptor-alpha (ER-alpha), and HE4 overexpressi

76 the expression of luminal markers, including estrogen receptor-alpha (ER-alpha, encoded by ESR1).

77 women, and over two-thirds of cases express estrogen receptor-alpha (ER-alpha, encoded by ESR1).

78 d unclear whether estrogen signaling through estrogen receptor-alpha (ER-alpha, Esr1) or ER-beta (Esr

79 itutive active/androstane receptor (CAR) KO, estrogen receptor alpha (ERalpha KO, phosphorylation-blo

80 Estrogen receptor alpha (ERalpha) activation functions A

81 Estrogen receptor alpha (ERalpha) activity is associated

82 opment is controlled by the balance of AR to estrogen receptor alpha (ERalpha) activity; either inhib

83 cals and drugs in three independent runs for estrogen receptor alpha (ERalpha) agonist and antagonist

84 demonstrate that Icaritin co-localizes with estrogen receptor alpha (ERalpha) and activates its nucl

85 GH-releasing hormone (GHRH) neurons express estrogen receptor alpha (ERalpha) and androgen receptor

86 environmental contaminant that can activate estrogen receptor alpha (ERalpha) and contribute to the

87 Approximately 75% of breast cancers express estrogen receptor alpha (ERalpha) and depend on estrogen

88 Approximately 70% of breast cancers express estrogen receptor alpha (ERalpha) and depend on this key

89 plexes involving RNA polymerase II (Pol II), estrogen receptor alpha (ERalpha) and ERalpha-pioneer fa

90 rficial spinal cord dorsal horn that express estrogen receptor alpha (ERalpha) and explored the behav

91 rapidly induced genes are enriched for both estrogen receptor alpha (ERalpha) and FOXA1 binding in t

92 miR-515-5p is transcriptionally repressed by estrogen receptor alpha (ERalpha) and functions as a tum

93 Estrogen receptor alpha (ERalpha) and progesterone recep

94 associates with transcriptional enhancers of estrogen receptor alpha (ERalpha) and that this associat

95 nto account the signaling cross-talk between estrogen receptor alpha (ERalpha) and the human epiderma

96 The development of tamoxifen and subsequent estrogen receptor alpha (ERalpha) antagonists represents

97 Most breast cancers expressing the estrogen receptor alpha (ERalpha) are treated successful

98 This hypothesis was validated in the estrogen receptor alpha (ERalpha) ChIA-PET data.

99 s direct visualization and quantification of estrogen receptor alpha (ERalpha) DNA binding, co-regula

100 Estrogen receptor alpha (ERalpha) expression is critical

101 pid metabolism and body weight by repressing estrogen receptor alpha (ERalpha) expression.

102 Notably, mice with selective deletion of estrogen receptor alpha (ERalpha) from Kiss1 neurons sho

103 Somatic mutations in the estrogen receptor alpha (ERalpha) gene (ESR1), especiall

104 Nucleosomes prevent the binding of estrogen receptor alpha (ERalpha) in absence of ligand a

105 (CA12) is associated with the expression of estrogen receptor alpha (ERalpha) in breast cancer and i

106 ctions of glucocorticoid receptors (GRs) and estrogen receptor alpha (ERalpha) in breast cancer devel

107 and mobilization, processes that depend upon estrogen receptor alpha (ERalpha) in HSCs.

108 that conditional knockout (cKO) mice lacking estrogen receptor alpha (ERalpha) in oviduct and uterine

109 Activation of estrogen receptor alpha (ERalpha) in the brain prevents

110 Here, we ablate estrogen receptor alpha (ERalpha) in the medial basal hy

111 Estrogen receptor alpha (ERalpha) is a critical prognost

112 Estrogen receptor alpha (ERalpha) is a key regulator of

113 Estrogen receptor alpha (ERalpha) is a key transcription

114 Estrogen receptor alpha (ERalpha) is a ligand-activated

115 Estrogen receptor alpha (ERalpha) is a ligand-dependent

116 Estrogen receptor alpha (ERalpha) is a major regulator o

117 Estrogen receptor alpha (ERalpha) is a master driver of

118 Estrogen receptor alpha (ERalpha) is an important target

119 The estrogen receptor alpha (ERalpha) is expressed in approx

120 Estrogen receptor alpha (ERalpha) is highly expressed in

121 The estrogen receptor alpha (ERalpha) is highly expressed in

122 Estrogen receptor alpha (ERalpha) is initially expressed

123 Estrogen receptor alpha (ERalpha) is involved in numerou

124 To assess this, we developed a point mutant estrogen receptor alpha (ERalpha) knockin mouse (C451A)

125 Global estrogen receptor alpha (ERalpha) knockout (KO) mice exh

126 All compounds were high affinity estrogen receptor alpha (ERalpha) ligands but displayed

127 Estrogen receptor alpha (ERalpha) mediates the effects o

128 The human estrogen receptor alpha (ERalpha) mediates the prolifera

129 Early studies indicated that estrogen receptor alpha (ERalpha) might impact the progr

130 Estrogen receptor alpha (ERalpha) modulates gene express

131 ival rates of breast cancer patients lacking estrogen receptor alpha (ERalpha) negatively correlated

132 t there is possible neuroendocrine action of estrogen receptor alpha (ERalpha) on the skeleton.

133 Estrogens can signal through either estrogen receptor alpha (ERalpha) or beta (ERbeta) to am

134 thesized that upregulating the expression of estrogen receptor alpha (ERalpha) or estrogen receptor b

135 Drugs that inhibit estrogen receptor alpha (ERalpha) or that block the prod

136 More than 75% of breast cancers are estrogen receptor alpha (ERalpha) positive (ER+), and re

137 D538G is common after endocrine therapy for estrogen receptor alpha (ERalpha) positive breast cancer

138 Almost 70% of breast cancers are estrogen receptor alpha (ERalpha) positive.

139 Estrogen triggers transactivation coupled estrogen receptor alpha (ERalpha) proteolysis, but mecha

140 ng nodules are estrogen dependent and retain estrogen receptor alpha (ERalpha) reactivity, but have d

141 Estrogen receptor alpha (ERalpha) regulates gene transcr

142 The DNA-binding sites of estrogen receptor alpha (ERalpha) show great plasticity

143 Estrogen receptor alpha (ERalpha) signaling leads to cel

144 cell line MCF7, which expresses a functional estrogen receptor alpha (ERalpha) signaling pathway.

145 wledge previously unreported, a role whereby estrogen receptor alpha (ERalpha) signaling preferential

146 In vitro, estrogen receptor alpha (ERalpha) signaling through meta

147 nd animal model results linking estrogen and estrogen receptor alpha (ERalpha) to CxCa, ERalpha expre

148 lective loss- or gain-of-function mutants of estrogen receptor alpha (ERalpha) to define two distinct

149 nding and transcriptional activation through estrogen receptor alpha (ERalpha) to that of 17beta-estr

150 P140 in breast cancer and its involvement in estrogen receptor alpha (ERalpha) transcriptional regula

151 ecule antagonist of the transcription factor estrogen receptor alpha (ERalpha) used to treat breast c

152 regulates gene transcription through nuclear estrogen receptor alpha (ERalpha) via 2 activation funct

153 s missense mutation in the gene encoding the estrogen receptor alpha (ERalpha) was previously identif

154 rogen-based therapies are mainly mediated by estrogen receptor alpha (ERalpha), a nuclear receptor th

155 ivator-6 (NCOA6), a reported coactivator for estrogen receptor alpha (ERalpha), actually attenuates E

156 he genome-wide chromatin-binding profiles of estrogen receptor alpha (ERalpha), along with the epigen

157 otein 14-3-3sigma and a peptide derived from Estrogen Receptor alpha (ERalpha), an important breast c

158 strogens drive breast carcinogenesis via the estrogen receptor alpha (ERalpha), androgens play a crit

159 gen-responsive genes, vitellogenin (VTG) and estrogen receptor alpha (ERalpha), as well as the androg

160 Treatment of female rats with antisense to estrogen receptor alpha (ERalpha), but not beta (ERbeta)

161 The classical estrogen receptor alpha (ERalpha), but not ERbeta, in th

162 ons of E2 with one of its cognate receptors, estrogen receptor alpha (ERalpha), estrogen receptor bet

163 Estrogen, via estrogen receptor alpha (ERalpha), exerts several benefi

164 We show that estrogen, acting via estrogen receptor alpha (ERalpha), induces rapid anticip

165 campus of female rats through a sex-specific estrogen receptor alpha (ERalpha), mGluR, and endocannab

166 e-negative breast cancer (TNBC), which lacks estrogen receptor alpha (ERalpha), progesterone receptor

167 The transcriptional activity of estrogen receptor alpha (ERalpha), the key driver of bre

168 ntermembrane space (IMS) and mediated by the estrogen receptor alpha (ERalpha), was found to upregula

169 Female lupus-prone NZM2410 estrogen receptor alpha (ERalpha)-deficient mice are pro

170 Estrogen receptor alpha (ERalpha)-estrogen response elem

171 Estradiol acts via estrogen receptor alpha (ERalpha)-expressing afferents o

172 Herein, we investigated the estrogen receptor alpha (ERalpha)-mediated EA of six new

173 Obesity is a risk factor for postmenopausal estrogen receptor alpha (ERalpha)-positive (ER(+)) breas

174 ty to antiestrogens and chemotherapeutics in estrogen receptor alpha (ERalpha)-positive and triple-ne

175 Recurrent estrogen receptor alpha (ERalpha)-positive breast and ov

176 hway in 20% to 40% of cases, particularly in estrogen receptor alpha (ERalpha)-positive breast cancer

177 One third of the patients with estrogen receptor alpha (ERalpha)-positive breast cancer

178 Patients with estrogen receptor alpha (ERalpha)-positive breast cancer

179 s COX-2 activity, is associated with reduced estrogen receptor alpha (ERalpha)-positive breast cancer

180 y used endocrine agents for the treatment of estrogen receptor alpha (ERalpha)-positive breast cancer

181 ourse of estradiol (E2) stimulation in human estrogen receptor alpha (ERalpha)-positive breast cancer

182 Many estrogen receptor alpha (ERalpha)-positive breast cancer

183 Many estrogen receptor alpha (ERalpha)-positive breast cancer

184 ly able to reduce DCIS risk in patients with estrogen receptor alpha (ERalpha)-positive disease.

185 herapy occurs in virtually all patients with estrogen receptor alpha (ERalpha)-positive metastatic br

186 ion and histone modifications, are linked to estrogen receptor alpha (ERalpha)-positive tumors and di

187 e: estrogen receptor 1 (ESR1), which encodes estrogen receptor alpha (ERalpha).

188 of BSEP by E2 in vitro and in vivo required estrogen receptor alpha (ERalpha).

189 ported to involve the activation of CHOP and estrogen receptor alpha (ERalpha).

190 the activation and nuclear translocation of estrogen receptor alpha (ERalpha).

191 ling pathways that include the estrogen (E2)-estrogen receptor alpha (ERalpha).

192 fully applied for detection of the biomarker estrogen receptor alpha (ERalpha).

193 which can be eliminated by an antagonist of estrogen receptor alpha (ERalpha).

194 ene has captured ESR1, the gene that encodes estrogen receptor alpha (ERalpha); as a result, this gen

195 Normal osteoblasts express estrogen receptor alpha (ERalpha); however, osteosarcoma

196 ERT) mRNA expression and cell growth through estrogen receptor-alpha (ERalpha) activation in ovarian

197 Estrogen receptor-alpha (ERalpha) activity in the brain

198 as a critical role in the regulation of both estrogen receptor-alpha (ERalpha) and c-ErbB2/HER2 (Her2

199 ently identified LMTK3 as a regulator of the estrogen receptor-alpha (ERalpha) and wished to understa

200 t regimens for breast cancer that target the estrogen receptor-alpha (ERalpha) are effective, but acq

201 is rescue was accompanied by an induction in estrogen receptor-alpha (ERalpha) expression and that co

202 Estrogen receptor-alpha (ERalpha) has central role in ho

203 The levels of estrogen receptor-alpha (ERalpha) impact breast cancer c

204 s shown to be a transcriptional activator of estrogen receptor-alpha (ERalpha) in ERalpha-positive br

205 The detection of estrogen receptor-alpha (ERalpha) in osteoblasts and ost

206 blocked in female mice specifically lacking estrogen receptor-alpha (ERalpha) in serotonin (5-HT) ne

207 Estrogen receptor-alpha (ERalpha) is a central transcrip

208 Estrogen receptor-alpha (ERalpha) is an important biomar

209 p) on neutralizing epigenetic aberrations in estrogen receptor-alpha (ERalpha) leading to enhanced an

210 that resveratrol acts as a pathway-selective estrogen receptor-alpha (ERalpha) ligand to modulate the

211 Estrogen receptor-alpha (ERalpha) mediates the essential

212 1 (GCM1), frizzled 5 (FZD5), WNT2, Sp1, and estrogen receptor-alpha (ERalpha) mRNA, were markedly up

213 models that allow for selective deletion of estrogen receptor-alpha (ERalpha) or selective inhibitio

214 Estrogen receptor-alpha (ERalpha) plays an important rol

215 o differentiates primary tumors to a benign, Estrogen Receptor-alpha (ERalpha) positive, Rictor-negat

216 Approximately 75% of breast cancers are estrogen receptor-alpha (ERalpha) positive, underscoring

217 provided a detailed view of the mechanism of estrogen receptor-alpha (ERalpha) regulated gene transcr

218 We show that activation of estrogen receptor-alpha (ERalpha) stimulates neural firi

219 or glucose homeostasis primarily through the estrogen receptor-alpha (ERalpha), but the respective im

220 males and females is primarily mediated via estrogen receptor-alpha (ERalpha), encoded by the Esr1 g

221 er subtypes are defined by the expression of estrogen receptor-alpha (ERalpha)-associated genes, many

222 red methylation that preferentially affected estrogen receptor-alpha (ERalpha)-binding genes.

223 Here we report that estrogen receptor-alpha (ERalpha)-expressing neurons in

224 ns, and induced proliferation in parallel in estrogen receptor-alpha (ERalpha)-negative mammary cells

225 herapy resistance remains a major problem in estrogen receptor-alpha (ERalpha)-positive breast cancer

226 nefitted tremendously from the generation of estrogen receptor-alpha (ERalpha)-targeted therapies, bu

227 of breast cancers are driven by estrogen via estrogen receptor-alpha (ERalpha).

228 rotein 90 chaperone complexes, together with estrogen receptor-alpha (ERalpha).

229 This process is mediated by estrogen receptor-alpha (ERalpha).

230 thelial cells through mechanisms mediated by estrogen-receptor alpha (ERalpha).

231 s the estrogen receptor needed for feedback (estrogen receptor alpha [ERalpha]); kisspeptin neurons i

232 e), and mice with knockout of Esr1, encoding estrogen receptor alpha (ERalphaKO mice), to analyze int

233 this effect was absent in mice lacking liver estrogen receptor alpha (Esr1) (LERKO mice).

234 The results showed an increase in estrogen receptor alpha (esr1) and vitellogenin (vtg) ge

235 uctal epithelial cells are regulated through estrogen receptor alpha (ESR1) but not estrogen receptor

236 In addition to known CYP3A4 TFs, estrogen receptor alpha (ESR1) emerges as key TF with th

237 -induced uterine cell growth, we removed the estrogen receptor alpha (Esr1) from mouse uterine stroma

238 VAMP7 colocalized with estrogen receptor alpha (ESR1) in the presence of its co

239 Importance: Estrogen receptor alpha (ESR1) mutations found in metast

240 ceptor gene, a mutation in the gene encoding estrogen receptor alpha (ESR1) was previously described

241 ear receptors (NRs) [androgen receptor (Ar), estrogen receptor alpha (Esr1), estrogen receptor beta (

242 n receptor (Ahr), interleukin-1 beta (Il1b), estrogen receptor alpha (Esr1), insulin like growth fact

243 ategies enabling neuron-specific deletion of estrogen receptor alpha (Esr1), we examine here whether

244 Here we identify estrogen receptor alpha (Esr1)-expressing cells in the p

245 egulation of gene expression (SATB1) and the estrogen receptor alpha (ESR1).

246 In rats, DES effects are mediated via Estrogen Receptor alpha (ESR1).

247 differentiation genes, mainly that encoding estrogen receptor alpha (Esr1/ERalpha).

248 ntromedial hypothalamus (VMHvl) that express estrogen receptor-alpha (Esr1) and progesterone receptor

249 Sustained expression of the estrogen receptor-alpha (ESR1) drives two-thirds of brea

250 Estrogen receptor-alpha (ESR1) expression was essentiall

251 coid receptor (GR/NR3C1) gene and one in the estrogen receptor-alpha (ESR1) gene were significant (q

252 Using wild-type (WT) and estrogen receptor-alpha (ESR1) knockout (KO) male mice,

253 etic studies highlight the potential role of estrogen receptor-alpha (ESR1) mutations, which show inc

254 5 orders of magnitude more sensitive, by an estrogen receptor alpha (EsRalpha)-dependent mechanism.

255 i3 channels that selectively mediate SOCE in estrogen receptor alpha-expressing (ERalpha(+)) breast c

256 hat promotes BC progression independently of estrogen receptor alpha expression.

257 Deletion of estrogen receptor alpha from B cells did not alter B cel

258 Estrogen receptor alpha gene (ESR1) mutations occur freq

259 intra-chromosomal gene fusion involving the estrogen receptor alpha gene ESR1, and another involving

260 of this study was to determine the effect of estrogen receptor-alpha gene (ESR1) mutations at the tyr

261 morphisms in the glucocorticoid receptor and estrogen receptor-alpha genes may modify the association

262 hormone receptor family (androgen receptor, estrogen receptor alpha, glucocorticoid receptor, minera

263 The bioreporter contains mutated human estrogen receptor alpha (hERalpha), called bisphenol A-t

264 e, in the induction of priming, regulated by estrogen receptor alpha in the nociceptor of female rats

265 Moreover, high levels of estrogen receptor alpha in these tumors enhanced the gro

266 e used the approach to probe the mobility of estrogen receptor-alpha in the vicinity of an integrated

267 tic variants across the ESR1 locus (encoding estrogen receptor alpha) in 118,816 subjects from three

268 Moreover, estrogen receptor alpha-ir colocalized with ERbeta-EGFP

269 Estrogen receptor alpha is known to up-regulate expressi

270 Estrogen receptor alpha is required for oviductal transp

271 ikewise, renal IRI was exacerbated in female estrogen receptor alpha-KO mice, while female mice recei

272 terically regulated Cas9 by insertion of the estrogen receptor-alpha ligand-binding domain.

273 Dysregulation of hypothalamic-pituitary estrogen receptor alpha-mediated signaling causes episod

274 uR1, depending on its activation by membrane estrogen receptor alpha (mERalpha; during diestrus) vers

275 nvasive cancers from controls were uniformly estrogen receptor alpha negative and undifferentiated, w

276 can cause DNA double-strand breaks (DSB) in estrogen receptor-alpha-negative breast cells and that B

277 acts bound to 17beta-estradiol (E2)-liganded estrogen receptor-alpha on estrogen response elements (E

278 rine ILC2s was observed in mice deficient in estrogen receptor alpha or estrogen receptor beta.

279 Metastatic, antiestrogen resistant estrogen receptor alpha positive (ER+) breast cancer is

280 estrogen receptor beta, with up to 20% being estrogen receptor alpha positive.

281 btained from 89 postmenopausal women who had estrogen receptor-alpha positive breast cancer and were

282 o a highly invasive mesenchymal phenotype in estrogen receptor alpha-positive (ERalpha(+)) breast can

283 old subunit in hPAFc, is highly expressed in estrogen receptor alpha-positive (ERalpha(+)) luminal br

284 und develop aggressive, highly aneuploid and estrogen receptor alpha-positive (ERalpha+) mammary aden

285 ndifferentiated, whereas well-differentiated estrogen receptor alpha-positive papillary invasive canc

286 is a well-tolerated, effective treatment for estrogen receptor-alpha-positive (ER+) breast cancer, bu

287 is associated with poor patient outcomes in estrogen receptor-alpha-positive (ERalpha(+)) breast can

288 17q23 and 20q13 were frequently amplified in estrogen receptor-alpha-positive luminal breast cancer.

289 Basal-like tumors typically lack estrogen receptor-alpha, progesterone receptor and HER2/

290 TNBC does not express estrogen receptor-alpha, progesterone receptor, or the H

291 however, currently used biomarkers, such as, estrogen receptor-alpha/progesterone receptor (ERalpha/P

292 Estrogen receptor -alpha signaling increased IL-33 relea

293 pDC innate functions through cell-intrinsic estrogen receptor alpha signaling, but did not exclude a

294 On the other hand, SORBS3 coactivated estrogen receptor alpha signaling, leading indirectly to

295 ymal transition in breast cancer through the estrogen receptor alpha/Slug axis and that it is a poten

296 extracellular signal-related kinase 1/2, and estrogen receptor alpha) that lead to acute cholestasis

297 get network, including GPER/GPR30 itself and estrogen receptor alpha, the plasma membrane Ca(2+)-ATPa

298 Silencing ATG7 or BECN1 caused estrogen receptor-alpha to exit the nucleus at the time

299 vity genes primarily sense signaling through estrogen receptor alpha, whereas the resistance genes mo

300 vity of oestrogen signalling is mediated via estrogen receptor alpha within the left gonad epithelium